Evaluating the clinical efficacy of Apixaban vs. Warfarin in patients with cerebral venous thrombosis (CVT)
Phase 4
Recruiting
- Conditions
- Cerebral venous thrombosis.Cerebral infarction due to cerebral venous thrombosis, nonpyogenicI63.6
- Registration Number
- IRCT20240217061039N1
- Lead Sponsor
- Ahvaz University of Medical Sciences
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Recruiting
- Sex
- All
- Target Recruitment
- 74
Inclusion Criteria
All patients over 18 years of age who are diagnosed with CVT in imaging
Exclusion Criteria
Not provided
Study & Design
- Study Type
- interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method
Related Research Topics
Explore scientific publications, clinical data analysis, treatment approaches, and expert-compiled information related to the mechanisms and outcomes of this trial. Click any topic for comprehensive research insights.
What molecular mechanisms underlie Apixaban's anticoagulant effect in cerebral venous thrombosis (CVT)?
How does Apixaban compare to Warfarin in preventing cerebral infarction in CVT patients with I63.6 diagnosis?
Are there specific biomarkers that predict response to direct oral anticoagulants like Apixaban in nonpyogenic CVT cases?
What are the potential adverse events associated with Apixaban versus Warfarin in CVT treatment and how are they managed?
What are the current combination therapies or competitor drugs for cerebral venous thrombosis beyond Apixaban and Warfarin?